Thyroid Medication Recall: Vitruvias Therapeutics USP 30 mg Lot 504950 Elevated to FDA Class I Over Superpotency
By Mike Joe WASHINGTON, Sept. 24, 2026. A nationwide thyroid medication recall covering one lot of Thyroid Tablets, USP 30 mg from Vitruvias Therapeutics, Inc. has drawn fresh attention after secondary reporting on Sept. 24 described an FDA Class I designation, the agency’s highest risk category The thyroid medication recall remains limited to Lot 504950. … Read more